Revenue Update on Provectus Biopharmaceuticals Inc(NYSEMKT:PVCT)

Provectus Biopharmaceuticals Inc(NYSEMKT:PVCT) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Earnings per share were $-0.02.

Provectus Biopharmaceuticals Inc (PVCT) shares turned negative on Wednesdays trading session with the shares closing down -0.0032 points or -1.24% at a volume of 3,95,093. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $0.2598. The peak price level was also seen at $0.2598 while the days lowest was $0.24. Finally the shares closed at $0.255. The 52-week high of the shares is $0.7 while the 52-week low is $0.178. According to the latest information available, the market cap of the company is $54 M.

Provectus Biopharmaceuticals Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers including metastatic melanoma liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis a type of eczema. All of its prescription drug candidates are in either the pre-clinical or clinical trial stage. In addition to clinical trials patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *